Tumor gene expression profiling characterizes breast cancer prognosis and chemotherapy response, as demonstrated by a randomized trial of the 21-gene recurrence score (RS) in early stage estrogen receptor and/or progesterone receptor (ER/PR)–positive, HER2-negative disease (5). The gene discussed is PGR; the disease is neoplasm.